Alnylam Pharmaceuticals
Open
$309.62
Prev. Close
$309.95
High
$310.71
Low
$309.09
Market Snapshot
$39.79B
126.8
-2.17
$2.25B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
emptyResult
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Recently from Cashu
Alnylam Pharmaceuticals Innovates RNAi Therapeutics Amid Economic Volatility and Market Challenges
Alnylam Pharmaceuticals: Pioneering RNAi Therapeutics in a Volatile Market Landscape Amidst the recent volatility in financial markets, Alnylam Pharmaceuticals continues to innovate within the biophar…
Alnylam Pharmaceuticals: Leading Innovation in Rare Genetic Disorder Treatments and Patient Care
Alnylam Pharmaceuticals: Pioneering Treatments for Rare Genetic Conditions Alnylam Pharmaceuticals is carving a significant niche in the biotech sector with its innovative approach to addressing rare…
Alnylam Pharmaceuticals: Pioneering Innovative Treatments for Rare Genetic Disorders
Alnylam Pharmaceuticals: Leading the Charge in Rare Disease Treatment Alnylam Pharmaceuticals stands at the forefront of biopharmaceutical innovation, particularly in the realm of rare genetic disorde…
Alnylam Pharmaceuticals Partners with Tenaya to Innovate Cardiovascular Disease Therapies
Alnylam Pharmaceuticals Fuels Innovation in Cardiac Disease Therapy through Strategic Collaboration with Tenaya Therapeutics Alnylam Pharmaceuticals Inc. enters into a noteworthy collaboration with Te…